Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Infectious Disease Therapeutics Market: By Drug class, By disease indication, By Distribution channel, and Region Forecast 2020-2031
Infectious disease therapeutics market size was valued at US$ 150.9 billion in 2024 and is expected to reach US$ 255.3 billion by 2031, growing at a significant CAGR of 7.8% from 2025-2031. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market.
For instance, in August 2016, Pfizer acquired AstraZeneca's late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics industry.
Study Period
2025-2031Base Year
2024CAGR
7.8%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of market.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 150.9 billion |
Market Size in 2031 |
US$ 255.3 billion |
Market CAGR |
7.8% |
By Drug Class |
|
By Disease Indication |
|
By Distribution Channel |
|
Download Free Sample Report
Infectious disease therapeutics market size was valued at US$ 150.9 billion in 2024 and is expected to reach US$ 255.3 billion by 2031, growing at a significant CAGR of 7.8%.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary |
2.Global Infectious Disease Therapeutics Market Introduction |
2.1.Global Infectious Disease Therapeutics Market - Taxonomy |
2.2.Global Infectious Disease Therapeutics Market - Definitions |
2.2.1.Drug Class |
2.2.2.Disease Indication |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Infectious Disease Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Infectious Disease Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Infectious Disease Therapeutics Market By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Anti-Bacterial |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anti-Viral |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Anti-Parasite |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Anti-Fungal |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Infectious Disease Therapeutics Market By Disease Indication, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. HIV/AIDS |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Influenza |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Hepatitis |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Malaria |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. TB |
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Infectious Disease Therapeutics Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospital Pharmacy |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacy |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Infectious Disease Therapeutics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Anti-Bacterial |
9.1.2.Anti-Viral |
9.1.3.Anti-Parasite |
9.1.4.Anti-Fungal |
9.1.5.Others |
9.2. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.HIV/AIDS |
9.2.2.Influenza |
9.2.3.Hepatitis |
9.2.4.Malaria |
9.2.5.TB |
9.2.6.Others |
9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacy |
9.3.2.Retail Pharmacy |
9.3.3.Others |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Anti-Bacterial |
10.1.2.Anti-Viral |
10.1.3.Anti-Parasite |
10.1.4.Anti-Fungal |
10.1.5.Others |
10.2. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.HIV/AIDS |
10.2.2.Influenza |
10.2.3.Hepatitis |
10.2.4.Malaria |
10.2.5.TB |
10.2.6.Others |
10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacy |
10.3.2.Retail Pharmacy |
10.3.3.Others |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Anti-Bacterial |
11.1.2.Anti-Viral |
11.1.3.Anti-Parasite |
11.1.4.Anti-Fungal |
11.1.5.Others |
11.2. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.HIV/AIDS |
11.2.2.Influenza |
11.2.3.Hepatitis |
11.2.4.Malaria |
11.2.5.TB |
11.2.6.Others |
11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacy |
11.3.2.Retail Pharmacy |
11.3.3.Others |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Anti-Bacterial |
12.1.2.Anti-Viral |
12.1.3.Anti-Parasite |
12.1.4.Anti-Fungal |
12.1.5.Others |
12.2. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.HIV/AIDS |
12.2.2.Influenza |
12.2.3.Hepatitis |
12.2.4.Malaria |
12.2.5.TB |
12.2.6.Others |
12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacy |
12.3.2.Retail Pharmacy |
12.3.3.Others |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Infectious Disease Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Anti-Bacterial |
13.1.2.Anti-Viral |
13.1.3.Anti-Parasite |
13.1.4.Anti-Fungal |
13.1.5.Others |
13.2. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.HIV/AIDS |
13.2.2.Influenza |
13.2.3.Hepatitis |
13.2.4.Malaria |
13.2.5.TB |
13.2.6.Others |
13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacy |
13.3.2.Retail Pharmacy |
13.3.3.Others |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.GlaxoSmithKline Plc (U.K.) |
14.2.2.Johnson & Johnson Services, Inc. (U.S.) |
14.2.3.Merck & Co, Inc. (U.S.) |
14.2.4.Pfizer Inc. (U.S.) |
14.2.5.Novartis AG. (Switzerland) |
14.2.6.AbbVie Inc. (U.S.) |
14.2.7.Astellas Pharma Inc. (Japan) |
14.2.8.AstraZeneca (U.K.) |
14.2.9.Auritec Pharmaceuticals Inc. (U.S.) |
14.2.10.Bayer AG (Germany) |
14.2.11.Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.) |
14.2.12.Chimerix Inc. (U.S.) |
14.2.13.Eli Lilly and Company (U.S.) |
14.2.14.Isis Pharmaceuticals (U.S.) |
14.2.15.Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan) |
14.2.16.Sanofi S.A. (France) |
14.2.17.Gilead Sciences (U.S.) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players